用于治疗无氧性皮肤炎的生物药物:有效性,安全性和未来方向
Marjolein S de Bruin-Weller1, Celeste M Boesjes1, Roselie A Achten1
1National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, the Netherlands.
Allergy
|September 24, 2025
概括
亚托匹性皮炎 (AD) 治疗已经进步,有针对性的生物疗法,如dupilumab,阻断关键的炎症性细胞因子. 本综述检查了关于这些严重AD管理的有效和安全选择的现实数据.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 亚托匹性皮肤炎 (AD) 是一种常见的慢性炎症性皮肤病,严重程度各不相同.
- 严重的AD往往需要全身治疗,历史上受到毒性和疗效的限制.
- 最近的进展集中在针对性的生物疗法,由于对AD病理生理学的理解得到了改善.
研究的目的:
- 审查关于阿托皮性皮肤炎生物疗法的有效性和安全性的现实数据.
- 为这些新型治疗方法的使用和副作用管理提供临床指导.
- 简要讨论临床试验后期阶段新出现的治疗点.
主要方法:
- 对阿尔茨海默病的生物制剂的现实世界证据的系统审查.
- 对dupilumab,tralokinumab,lebrikizumab和nemolizumab的数据进行分析.
- 包括关于细胞因子标 (IL-4,IL-13,IL-31) 和它们的作用的信息.
主要成果:
- 生物疗法在控制严重的AD和缓解症状方面表现出有效性.
- 与传统的免疫抑制剂相比,这些向性药物提供了更好的安全性.
- 现实世界的数据支持已批准的生物制剂的疗效和耐受性.
结论:
- 有针对性的生物疗法在管理中度至重度的亚托皮性皮肤炎方面取得了重大进展.
- 临床指导对于优化患者的治疗结果和管理潜在的不良事件至关重要.
- 对新的治疗点的持续研究有望进一步改善AD治疗.
相关概念视频
Drug Products: Biologics, Biosimilars and Interchangeables
235
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
235
Inflammatory Bowel Disease IV: Pharmacological Management
521
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
521
Microorganisms in Medicine and Therapeutics
982
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
982
Biopharmaceutical Factors Influencing Drug Product Design: Overview
233
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
233
Biopharmaceutics and Pharmacokinetics: Overview
3.3K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
3.3K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
492
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
492


